Actively Recruiting
Phase 2 Study of Preoperative Chemotherapy, Pembrolizumab, and Low or High Dose Radiation in Node-Positive Triple Negative Breast Cancer
Led by UNC Lineberger Comprehensive Cancer Center · Updated on 2026-04-27
32
Participants Needed
1
Research Sites
217 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the best radiation dose to stimulate an immune response when combined with an immune checkpoint inhibitor in patients with operable, lymph node-positive, triple negative breast cancer. This phase 2 study is part of the larger P-RAD trial and focuses on patients eligible for standard neoadjuvant chemo-immunotherapy based on the KEYNOTE-522 trial. The goal is to find the optimal radiation dose that works with pembrolizumab in this breast cancer type. Participants will be randomly assigned to receive either a low dose radiation boost 9Gy total or a high dose radiation boost 24Gy total delivered to the intact breast tumor over three days. Pembrolizumab 200 mg intravenously will be given within two days of starting radiation. After radiation and a research biopsy, patients will receive standard neoadjuvant chemotherapy and pembrolizumab. Surgery to remove the breast tumor and lymph nodes will follow, and then standard adjuvant therapy will be given as needed. During the study, patients will have biopsies before and after treatment to assess immune response. Researchers will monitor cancer response at surgery around 24 weeks, evaluating tumor and lymph node status, immune cell changes, and adverse events. Quality of life questionnaires will be completed at several points up to three years. Patients will be followed every six months for three years, then yearly for up to five years to track long-term safety and disease outcomes.
CONDITIONS
Brief Title
Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer
Research Team
T
Taylor Pierce
E
Emily L Schworer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here